Dyslipidemic drugs in metabolic syndrome. - Wikidata - wikimedia - TriplyDB

Dyslipidemic drugs in metabolic syndrome.

Dyslipidemic drugs in metabolic syndrome.

http://www.wikidata.org/entity/Q37016008

about

Lipid-lowering efficacy of rosuvastatin Antidyslipidemic drugs in metabolic syndrome.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.

P2860

Q24187891-5CC94B7C-B815-4B2F-A11F-0343B34D0A70 Q42776099-6D455A6B-E5DC-4B8B-95DF-90B97D8BBE22 Q51304354-3C6F910B-D575-4863-91BB-A2A0D58ADADB

P2860

Dyslipidemic drugs in metabolic syndrome.

http://www.wikidata.org/entity/Q37016008

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dyslipidemic drugs in metabolic syndrome.

@en

Dyslipidemic drugs in metabolic syndrome.

@nl

type

label

Dyslipidemic drugs in metabolic syndrome.

@en

Dyslipidemic drugs in metabolic syndrome.

@nl

prefLabel

Dyslipidemic drugs in metabolic syndrome.

@en

Dyslipidemic drugs in metabolic syndrome.

@nl

P1433

Q37016008-5A2C0559-81C2-4126-BD49-4A1A0FFAFFF1

P1476

Q37016008-0146A2F1-6FE6-49A4-9E1D-29672C642E15

P2093

Q37016008-55014FC2-3BF0-4E9A-857B-B9E2576ADA22

Q37016008-B30B14E5-0984-4138-A33F-7707D4243705

Q37016008-DDEF3C78-E209-4A8C-A4F9-58C917A6457F

Q37016008-E6368C0A-339A-400D-8912-9F315678ECA7

P2860

Q37016008-034D0BAD-D654-47FA-9AA4-8931F02B9435

Q37016008-061E037C-56B3-4FF4-9A95-49FDAD786757

Q37016008-0B5BB5B7-22E2-4AD0-B48F-8F4ECF0D03C4

Q37016008-18896CC1-616F-4E42-B06D-D292922B1C4E

Q37016008-1C0F768D-CFC7-4E7B-B6DA-84905A09314F

Q37016008-1D086992-8E8C-48A6-B1C7-396F5931F742

Q37016008-2A50DDF2-B195-40E6-8DB3-346D1BD1D068

Q37016008-2AC7B799-BB74-4834-8871-93ACCC6141A6

Q37016008-2F6C4563-7231-4A12-BB6E-2D7D7F3AA17F

Q37016008-3715A5DD-4292-4663-A09A-0CC25B951A4E

P304

Q37016008-1A0FA647-0FA6-47ED-BA7B-FB2CEAB65BF1

P31

Q37016008-4E5191D1-55B5-44B6-94B9-DC089FE5442C

P356

Q37016008-B43032FC-896B-453A-9FB4-15EDB751714A

P433

Q37016008-EA2D8976-BE01-4AEA-81A5-08DE29DF5CC7

P478

Q37016008-AC29CA9F-AB82-475B-9022-26FB6091DE67

P50

Q37016008-0608CCC3-1C44-4651-B2A2-10B3ABB9B16B

P577

Q37016008-BA91BB73-421B-4BD8-8BA3-39E142F78179

P5875

Q37016008-4C5163FF-829A-42F1-900B-7083F0FA5613

P698

Q37016008-C68C7ADC-47B8-4BB6-B79B-70E6F29AFF5D

P921

Q37016008-FED5F6D3-0061-4D65-80D0-06D7040B5DC0

P932

Q37016008-5F316224-E139-4314-93E8-2DFCD053FDE7

P356

2230-8210.111644

P1433

Indian Journal of Endocrinology and Metabolism

P1476

Dyslipidemic drugs in metabolic syndrome

@en

P2093

Asad U Khan

http://www.w3.org/2001/XMLSchema#string

Farida Ahmad

http://www.w3.org/2001/XMLSchema#string

Misbahuddin

http://www.w3.org/2001/XMLSchema#string

Sheelu S Siddiqi

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

A method for estimating the probability of adverse drug reactions

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

P304

472-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2230-8210.111644

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

250920413

http://www.w3.org/2001/XMLSchema#string

P698

23869305

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

3712379

http://www.w3.org/2001/XMLSchema#string